Monopar Therapeutics (MNPR) Research & Development (2017 - 2025)
Quarterly results put Research & Development at $2.6 million for Q3 2025, up 163.11% from a year ago — trailing twelve months through Sep 2025 was $6.9 million (up 56.48% YoY), and the annual figure for FY2024 was $4.0 million, changed.
Monopar Therapeutics has reported Research & Development over the past 9 years, most recently at $2.6 million for Q3 2025.
- Research & Development reached $2.6 million in Q3 2025 per MNPR's latest filing, up from $1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $2.6 million in Q3 2025 and bottomed at $918634.0 in Q4 2024.
- Median Research & Development over the past 5 years was $1.6 million (2023), compared with a mean of $1.6 million.
- The largest annual shift saw Research & Development skyrocketed 250.39% in 2021 before it crashed 41.57% in 2024.
- Over 5 years, Research & Development stood at $2.0 million in 2021, then grew by 6.07% to $2.1 million in 2022, then plummeted by 37.4% to $1.3 million in 2023, then plummeted by 30.22% to $918634.0 in 2024, then skyrocketed by 181.91% to $2.6 million in 2025.
- Business Quant data shows Research & Development for MNPR at $2.6 million in Q3 2025, $1.7 million in Q2 2025, and $1.6 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 918,634.00 |
| Sep 30, 2024 | 984,278.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 966,110.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.48 Mn |
| Mar 31, 2021 | 1.21 Mn |
| Dec 31, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.26 Mn |
| Jun 30, 2020 | 832,503.00 |
| Mar 31, 2020 | 344,407.00 |
| Dec 31, 2019 | 583,778.00 |
| Sep 30, 2019 | 219,846.00 |
| Jun 30, 2019 | 329,294.00 |
| Mar 31, 2019 | 835,600.00 |
| Dec 31, 2018 | 520,982.00 |
| Sep 30, 2018 | 303,684.00 |
| Jun 30, 2018 | 303,684.00 |
| Mar 31, 2018 | 457,141.00 |
| Dec 31, 2017 | 309,315.00 |
| Sep 30, 2017 | 180,675.00 |
| Jun 30, 2017 | 311,593.00 |
| Mar 31, 2017 | 133,736.00 |